In Osteoporosis Osteoporosis is a common condition that causes bones to become fragile and brittle so that they break (fracture) more easily. Fractures may be painful and restrict a person’s ability to carry out their normal daily tasks. Calinta Kit reduces the risk of a fracture occurring in osteoporosis. It also helps in the growth and development of bones as well as maintain strong bones. Since osteoporosis doesn’t usually have any symptoms such as pain (until a fracture occurs) you might not ‘feel’ any immediate benefit from your treatment with Calinta Kit. Keep taking it until your doctor asks you to stop. Along with medicines, eat a balanced diet rich in calcium and vitamin D like dairy products, green leafy vegetables etc.
It is unsafe to consume alcohol with Calinta Kit.
Calinta Kit may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Calinta Kit is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Calinta Kit does not usually affect your ability to drive.
Calinta Kit should be used with caution in patients with kidney disease. Dose adjustment of Calinta Kit may be needed. Please consult your doctor.
Calinta Kit is probably safe to use in patients with liver disease. Limited data available suggests that dose adjustment of Calinta Kit may not be needed in these patients. Please consult your doctor.
If you miss a dose of Calinta Kit, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular schedule. Do not double the dose.
FDC Ltd | B-8, MIDC Area, Waluj - 431 136, Dist. Aurangabad, Maharashtra
Marketer/Manufacturer: Abbott || ₹14.5/tablet (25% cheaper)
No customer reviews yet.
FDA approved prescribing information. Levocitrizine; 1995 [revised May 2007]. [Accessed 01 Apr. 2019] (online) Available from: Read More
European Medicne Agency. Revised assessment report: Ambroxol and bromhexine containing medicinal products. 2015. [Accessed 01 Apr. 2019] (online) Available from: Read More
ScienceDirect. Ambroxol. [Accessed 01 Apr. 2019] (online) Available from: Read More
Levocitrizine. Slough, Berkshire: UCB Pharma Limited; 2007 [revised 27 Mar. 2019]. [Accessed 01 Apr. 2019] (online) Available from: Read More